20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Bank of America analyst Steve Byrne raised the price objective on Aegerion Pharmaceuticals (NASDAQ: AEGR) from $58 to $100 and maintained a Buy rating. Byrne noted a strong global outlook and less risk to the drug PCSK9 as reasons for the increase.
In the report, Bank of America noted, "We raised our DCF-derived PO for AEGR from $58 to $100 based on several positive updates. Management stated that the US launch for Juxtapid (to treat high cholesterol in patients with a genetic condition called HoFH) has experienced better than expected trends in scripts written, payor coverage, and discontinuationrates. In addition, the CHMP delivered a unanimous opinion to approve the drug (called Lojuxta ex-US)."
The analysts now forecast a loss of $2.18 per share for 2013, better than the consensus loss of $2.24 per share, and expects EPS of $3.16 for 2014 vs. $0.55 consensus. The price target is also now the highest forecast on Wall St.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!